Compare AT&T Inc. (T) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs GeneDx Holdings Corp — how do they compare? AT&T Inc. trades at $22.68 (market cap $170.42B), while GeneDx Holdings Corp trades at $69.47 (market cap $2.02B). The key difference: AT&T Inc. is far larger — about 84.4× GeneDx Holdings Corp's market cap, and AT&T Inc. pays a 4.46% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold AT&T Inc. for 118 Days and GeneDx Holdings Corp for 19 Days on average.
| T | WGS | |
|---|---|---|
Market Cap | $170.42B | $2.02B |
Volume | 50,780,036 | 734,640 |
Sector | Media | Health |
52-Week High | $29.10 | $167.51 |
52-Week Low | $20.49 | $34.51 |
Typical Hold Time | 118 Days | 19 Days |
Enterprise Value | $315.74B | $2.05B |
Dividend Yield | 4.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $24.48, up 0.2% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.2, 16.9% net margin, and consistent dividend payments. Revenue grew to $125.7B in 2025, while debt reduction and fiber expansion with Corning highlight strategic initiatives. Analyst consensus is mixed with 44% buy ratings and a $27.61 price target.
The outlook balances value appeal against competitive pressures. The low valuation and 4% yield attract income investors, but legacy revenue declines and high debt pose risks. Fiber investments and wireless growth offer upside, yet execution and market saturation remain challenges. The stock presents a dividend-income opportunity with moderate growth potential in a competitive telecom landscape.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
